Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Spinal Cord Leptomenigeal Enhancement as a Marker of Myelitis Severity in Children with MOGAD
Autoimmune Neurology
S32 - Autoimmune Neurology: NMOSD/MOGAD (2:36 PM-2:48 PM)
009

Leptomeningeal inflammation has been recently reported in children with MOGAD as evidenced by enhancement of the spinal leptomeninges on post-contrast MRI. Whether sLME is associated with disease severity in MOGAD myelitis is unknown.

To characterize the clinical, CSF and MRI features associated with spinal cord leptomeningeal enhancement (sLME) in children with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

We included participants in the prospective Canadian Pediatric Demyelinating disease study with evidence of spinal lesion(s) on MRI, and for whom both gadolinium-enhanced MRI and serum MOG-IgG testing results were available. We compared clinical and MRI findings between participants with MOGAD myelitis and seronegative monophasic myelitis with and without evidence of sLME.

We included 33 children with MOGAD myelitis and 45 with seronegative monophasic myelitis. Spinal cord LME was observed in 20/33 children with MOGAD and in 13/45 children with seronegative myelitis.  Among children with MOGAD, sLME associated with higher frequency of longitudinally extensive lesions (95 vs 62%), H sign (75% vs 38%), spinal cord tumefactive lesions (50% vs 8%), complete cross-sectional involvement (80% vs 38%), nodular enhancement (35% vs 0%) and more spinal lesions (median 2 vs 1), (all p<0.05). No significant differences were found in the frequency of CSF oligoclonal bands (21% vs 13%). Only 5 children with MOGAD, all with sLME, experienced clinical relapses, while no relapses were reported among the 33 MOGAD children without sLME (p=0.13). Among children with seronegative myelitis, sLME associated with more spinal cord tumefactive lesions (40% vs 13%) and complete cross-section involvement (79% vs 42%) (all p<0.05).

Spinal cord LME, irrespective of MOG-IgG status, associates with more extensive spinal cord lesion severity (as defined by more extensive cross-sectional involvement and a tumefactive cord lesion appearance). The mechanism behind this association might provide insights into determinants of outcome and deserves further studies.

 

Authors/Disclosures
Serenella Bartiromo, MD (University of Verona)
PRESENTER
Dr. Bartiromo has nothing to disclose.
Cesar Alves (CHOP) No disclosure on file
Arastoo Vossough, MD (University of Pennsylvania - Children'S Hospital of Philadelphia) Dr. Vossough has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Syneos Health. Dr. Vossough has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for DeepSight. Dr. Vossough has received publishing royalties from a publication relating to health care.
Julia O'Mahony (The Hospital for Sick Children) Ms. O'Mahony has nothing to disclose.
E. Ann Yeh, MD, MA, FRCPC (Hosptial for Sick Children) Dr. Yeh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Yeh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PRIME. Dr. Yeh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Yeh has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Yeh has received research support from Biogen. The institution of Dr. Yeh has received research support from Stem Cell Network. The institution of Dr. Yeh has received research support from CIHR. The institution of Dr. Yeh has received research support from Ontario Institute for Regenerative Medicine. The institution of Dr. Yeh has received research support from National MS Society. The institution of Dr. Yeh has received research support from NIH. The institution of Dr. Yeh has received research support from SickKids Foundation. The institution of Dr. Yeh has received research support from CMSC. The institution of Dr. Yeh has received research support from MSSC.
Ruth-Ann Marrie, MD (University of Manitoba) The institution of Dr. Marrie has received research support from CIHR. The institution of Dr. Marrie has received research support from MS Canada. The institution of Dr. Marrie has received research support from National MS Society. The institution of Dr. Marrie has received research support from Crohn's and Colitis Canada. The institution of Dr. Marrie has received research support from US Department of Defense. The institution of Dr. Marrie has received research support from The Arthritis Society. The institution of Dr. Marrie has received research support from CMSC.
Sridar Narayanan (Montreal Neurological Institute) Sridar Narayanan has received personal compensation for serving as an employee of NeuroRx Research. Sridar Narayanan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech Inc.. The institution of Sridar Narayanan has received research support from Immunotec Inc.
Amit Bar-Or, MD, FRCPC (University of Pennsylvania) Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche Genentech. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen/Actelion. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atara Biotherapeutics. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merk/EMD Serono. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Atara Biotherapeutics. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck/EMD Serono. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. The institution of Dr. Bar-Or has received research support from Novartis. The institution of Dr. Bar-Or has received research support from Biogen. The institution of Dr. Bar-Or has received research support from Roche/Genentech. The institution of Dr. Bar-Or has received research support from Merck/EMD Serono.
Alberto Gajofatto (University of Verona) No disclosure on file
Brenda Banwell, MD, FAAN (Childrens Hospital of Philadelphia) Dr. Banwell has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Banwell has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Banwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Banwell has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Banwell has received research support from National MS Society. The institution of Dr. Banwell has received research support from NIH.
Giulia Fadda, MD (University of Ottawa) Dr. Fadda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics.